Medtronic appoints Marinaro president. Medtronic stock sits 6.43 percent below its high

Published on 10/27/2026 at 10:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Michael Marinaro became president effective October 14, 2026. Medtronic stock costs EUR 85.33 on October 27, 2026, 6.43 percent below its EUR 91.19 high.

Leadership and quarterly growth

Michael Marinaro assumed the Medtronic presidency effective October 14, 2026.
Fiscal first-quarter revenue rose 13.70 percent to USD 9.76 billion.
Medtronic stock trades at EUR 85.33 at 10:10 a.m. CET at Lang & Schwarz on October 27, 2026.
Medtronic is scheduled to report second-quarter fiscal 2027 results on November 17, 2026.

Medtronic plc, IE00BTN1Y115, Illustration mit AI erstellt.

Medtronic plc (ISIN IE00BTN1Y115) approved Michael Marinaro as president effective October 14, 2026, according to Boerse Express. The leadership change adds responsibility for Greater China while Geoffrey Martha remains chairman and chief executive officer.

Medtronic stock was trading at EUR 85.33 at Lang & Schwarz on October 27, 2026 at 10:10 a.m. CET. The price was 6.43 percent below the EUR 91.19 52-week high reported for the German quotation on October 26, 2026.

Leadership expands beyond MedSurg

Marinaro retained his existing responsibilities in the Medical Surgical Portfolio, Americas and global commercial operations, while adding oversight of Greater China. The appointment therefore broadens the operating remit of an existing executive rather than introducing an external chief executive, a distinction relevant as Medtronic reshapes its portfolio.

What does the growth mean for results?

Medtronic reported fiscal first-quarter 2027 revenue of USD 9.76 billion, up 13.70 percent from the same period a year earlier, while adjusted earnings per share reached USD 1.45 versus a USD 1.39 consensus estimate, according to MarketBeat. The company also raised fiscal 2027 organic revenue growth guidance to 7.25 percent to 7.75 percent from 6.75 percent to 7.25 percent, as reported by The Filing Desk.

Three dated developments

On October 14, 2026, Marinaro became president. On October 19, 2026, Medtronic received CE marking for five Vitalis pacemakers, according to Boerse Express. On October 22, 2026, registry results covered 1,050 Sphere-9 patients and 1,160 PulseSelect patients, with a 100.00 percent acute success rate for PulseSelect.

Next reporting date

Medtronic is expected to report second-quarter fiscal 2027 results before the market opens on November 17, 2026, with an earnings call scheduled for 8:00 a.m. ET, according to MarketBeat. Consensus estimates call for USD 1.33 in earnings per share and USD 9.48 billion in revenue for that quarter.

Stock price and investor context

The next results will test whether the 13.70 percent fiscal first-quarter revenue growth can persist after the MiniMed separation. Medtronic's fiscal 2026 revenue was USD 36.4 billion, up 8.40 percent, while operating margin was 17.80 percent, according to The Filing Desk. The comparison puts the latest quarterly acceleration against a slower full-year base.

Medtronic was trading at EUR 85.33 at Lang & Schwarz on October 27, 2026 at 10:10 a.m. CET.

The further course of trading is shown by the continuously updated real-time quote of Medtronic stock.